Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? - PubMed (original) (raw)

Review

. 1999 Jul 27;100(4):437-44.

doi: 10.1161/01.cir.100.4.437.

Affiliations

• PMID: 10421606
• DOI: 10.1161/01.cir.100.4.437

Review

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

R M Scarborough et al. Circulation. 1999.

Abstract

During the last decade, intensive efforts have been made to evaluate the role of the platelet glycoprotein (GP) IIb/IIIa complex in platelet-mediated thrombus formation. Significant efforts have also been made to design potent antagonists of this "final common pathway" of platelet aggregation to be used as novel therapeutic strategies to treat acute coronary syndromes. Although several different GP IIb/IIIa antagonists have convincingly demonstrated the usefulness of this platelet-directed therapeutic strategy, a number of lingering unsolved and sometimes misunderstood issues concerning the pharmacology and optimal clinical usefulness of these agents remain to be explored. This article reviews these issues, which include antagonist affinity, reversibility, and receptor specificity. Other issues are related to the effects of GP IIb/IIIa receptor availability, neoepitopes induced by antagonist binding with the potential to mediate thrombocytopenia, optimal methods of platelet monitoring and, perhaps ultimately, the potential therapeutic index of the oral class of GP IIb/IIIa antagonists. All of these specific issues are likely to be illuminated in the next several years, which will greatly determine the breadth of this therapeutic class.

PubMed Disclaimer

Similar articles

• [GP IIb/IIIa receptor antagonists--molecular and clinical aspects].
  Francuz T. Francuz T. Postepy Hig Med Dosw. 2001;55(3):419-32. Postepy Hig Med Dosw. 2001. PMID: 11505641 Review. Polish.
• Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
  Frelinger AL 3rd, Furman MI, Krueger LA, Barnard MR, Michelson AD. Frelinger AL 3rd, et al. Circulation. 2001 Sep 18;104(12):1374-9. doi: 10.1161/hc3701.095950. Circulation. 2001. PMID: 11560852
• Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
  Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B. Bednar RA, et al. J Pharmacol Exp Ther. 1998 Jun;285(3):1317-26. J Pharmacol Exp Ther. 1998. PMID: 9618439
• Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
  Ilveskero S, Lassila R. Ilveskero S, et al. Thromb Res. 2006;117(3):291-7. doi: 10.1016/j.thromres.2005.03.013. Thromb Res. 2006. PMID: 15878612
• Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors.
  Jennings LK, White MM. Jennings LK, et al. Am Heart J. 1998 May;135(5 Pt 2 Su):S179-83. doi: 10.1016/s0002-8703(98)70246-7. Am Heart J. 1998. PMID: 9588397 Review.

Cited by

• Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.
  van Werkum JW, Gerritsen WB, Kelder JC, Hackeng CM, Ernst SM, Deneer VH, Suttorp MJ, Rensing BJ, Plokker HW, Ten Berg JM. van Werkum JW, et al. Neth Heart J. 2007;15(11):375-81. doi: 10.1007/BF03086018. Neth Heart J. 2007. PMID: 18176639 Free PMC article.
• Current Status and Future Direction of Antithrombotic Therapy for Patients with STEMI Undergoing Primary PCI.
  Vogel RF, Delewi R, Badimon L, Angiolillo DJ, Vlachojannis GJ. Vogel RF, et al. Rev Cardiovasc Med. 2022 Sep 5;23(9):297. doi: 10.31083/j.rcm2309297. eCollection 2022 Sep. Rev Cardiovasc Med. 2022. PMID: 39077705 Free PMC article. Review.
• Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.
  Furman MI, Frelinger III AL, Michelson AD. Furman MI, et al. Curr Cardiol Rep. 2000 Sep;2(5):386-94. doi: 10.1007/s11886-000-0051-0. Curr Cardiol Rep. 2000. PMID: 10980905 Review.
• Using Drosophila behavioral assays to characterize terebrid venom-peptide bioactivity.
  Eriksson A, Anand P, Gorson J, Grijuc C, Hadelia E, Stewart JC, Holford M, Claridge-Chang A. Eriksson A, et al. Sci Rep. 2018 Oct 15;8(1):15276. doi: 10.1038/s41598-018-33215-2. Sci Rep. 2018. PMID: 30323294 Free PMC article.
• PKCalpha regulates platelet granule secretion and thrombus formation in mice.
  Konopatskaya O, Gilio K, Harper MT, Zhao Y, Cosemans JM, Karim ZA, Whiteheart SW, Molkentin JD, Verkade P, Watson SP, Heemskerk JW, Poole AW. Konopatskaya O, et al. J Clin Invest. 2009 Feb;119(2):399-407. doi: 10.1172/JCI34665. Epub 2009 Jan 19. J Clin Invest. 2009. PMID: 19147982 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.